Chronic rheumatoid arthritis (RA) is a result of inflammation of the joints. Inflammation is actually the body´s way of dealing with infections caused by bacteria, but in rheumatoid arthritis the immune system overreacts, attacking the body´s own tissues.

Inflammation is also involved in atherosclerosis (also called
hardening of the arteries). When fat is stored in blood vessels and becomes rancid, the body tries to rid itself of the fat by calling in so-called inflammatory cells, white corpuscles. But the reaction is often too powerful, so the inflammatory cells start to break down the walls of the vessels in the same way they break down joint cartilage and bone in rheumatoid arthritis.

A central role in inflammation in rheumatoid arthritis is played by a signal molecule called TNF-alpha. Heart scientist Stefan Jovinge can now show that TNF-alpha is also involved in atheromatosis/atherosclerosis. His research team first developed a special breed of mice that was prone to develop this disease, whereupon they knocked out the gene for TNF-alpha and found that the mice developed less atheromatosis/atherosclerosis.

The same result was achieved by giving these atheromatosis-conditioned mice a drug that impedes the effect of TNF in the body. The findings have recently been published in the journal “Arteriosclerosis, Thrombosis and Vascular Biology”.
At the same time, working with rheumatology units in southern Sweden, rheumatologist Lennart Jacobsson at Malmö University Hospital has studied the use of new TNF-inhibiting drugs on patients with chronic
rheumatic arthritis. In some 1,500 patients, the symptoms of the joint disorder were substantially alleviated, and at the same time the risk of coronary
disease-which otherwise is higher among these patients-fell to nearly half.

The two research teams are now carrying on their collaboration, which is unique in many ways and has attracted much international attention. Already roughly a fifth of all patients with rheumatoid arthritis in Malmö are treated with a TNF inhibitor, and Stefan
Jovinge hopes to be able to test the medicine on special groups of heart patients in about a year. If the theories hold true, in the future the drug may be
used for a large proportion of heart patients.

More information: Stefan Jovinge, phone: +46 40-33 78 44, +46 46- 222 30 82 or cell: +46 70-572 42 44 e-mail,
Lennart Jacobsson, phone: +46 40-33 10 00, e-mail

The article in the journal can be found at

Press release in Swedish and photos at